Triple Peptide Blend
Glow 60 mg represents a cutting-edge research formulation that synergistically combines three of the most powerful regenerative peptides into a single, comprehensive blend: BPC-157 (10 mg), TB-500 (10 mg), and GHK-Cu (40 mg). This meticulously engineered 60 mg total peptide complex is specifically designed for research into comprehensive tissue repair, skin rejuvenation, and systemic anti-aging. Each component brings unique mechanisms that complement and amplify the others: BPC-157 provides exceptional healing and anti-inflammatory properties, TB-500 enhances cellular migration and angiogenesis, while GHK-Cu stimulates collagen/elastin synthesis and provides antioxidant protection. Together, they create a multi-targeted research tool that addresses tissue repair from cellular to systemic levels.
For bodybuilders, athletes, and anti-aging researchers in the USA, Dragon Pharma Glow 60 mg offers unprecedented convenience and synergistic potential for studying comprehensive recovery and rejuvenation. The blend is particularly valuable for research on skin quality improvement, scar reduction, connective tissue repair, joint health, and overall tissue resilience. The 60 mg total concentration—with its distinctive blue tint from the GHK-Cu component—provides ample material for extended research protocols. This pre-formulated blend eliminates the need for researchers to source, measure, and combine three separate peptides, ensuring consistent ratios and reducing potential errors. Manufactured by Dragon Pharma under strict pharmaceutical-grade conditions in certified European facilities, each vial guarantees precise 1:1:4 ratio blending and maximum purity for reliable experimental outcomes across dermatological, orthopedic, and regenerative medicine research applications.
Key Benefits:
Each 2 mL vial contains a precisely blended 60 mg peptide complex: 10 mg BPC-157, 10 mg TB-500, and 40 mg GHK-Cu as a sterile lyophilized powder with characteristic blue coloration from the copper peptide, manufactured under Dragon Pharma's exacting pharmaceutical-grade standards.
| Product Name | Glow 60 mg |
| Manufacturer | Dragon Pharma |
| Substance | BPC-157 + TB-500 + GHK-Cu Blend |
| Packaging | 2 mL glass vial, lyophilized blue-tinged powder |
| Lab Test Result | Precise 1:1:4 ratio blend (≥98% purity each component) |
| Half-Life | Varies by component: BPC-157 (hours), TB-500 (~1-2 weeks), GHK-Cu (~2 hours) |
| Recommended Cycle | Research cycles: 4-8 weeks for acute injury/skin studies, 8-12 weeks for systemic anti-aging research. |
| Form | Lyophilized (freeze-dried) powder blend for reconstitution |
| Aromatization | Not applicable (non-hormonal peptide blend) |
| Dosage (Research Models) | Studied with various protocols: daily subcutaneous, topical application, or localized near injury/skin areas. |
Research Application Only: This information summarizes scientific literature for educational context. Dragon Pharma Glow 60 mg is a research chemical for laboratory investigation, not for human consumption.
In experimental settings, the Glow blend is reconstituted with bacteriostatic water. The resulting solution will have a blue tint from the GHK-Cu component, confirming proper peptide blending. Research administration routes include: 1) Subcutaneous injection (for systemic effects or localized near areas of interest), 2) Topical application (mixed into creams, gels, or serums for skin studies), and 3) Occasionally intramuscular near injury sites. The varied half-lives of the components (BPC-157: hours; TB-500: weeks; GHK-Cu: hours) create both immediate and sustained effects, making daily or every-other-day administration common in research protocols. For skin-focused studies, combination approaches (systemic + topical) often yield the most comprehensive results.
As a non-hormonal peptide blend, Glow does not affect the HPTA, so traditional PCT with SERMs like Clomid is not applicable. The research focus is maintaining tissue health after cessation. Protocols might transition to maintenance dosing of individual components or switch to supportive compounds like SS-31 for mitochondrial health. For ongoing skin research, topical antioxidants or lower-dose GHK-Cu 10 mg could be incorporated into follow-up studies.
The Glow blend itself is synergistic, but can be studied alongside other compounds for enhanced effects. For maximal recovery research, combining with growth hormone secretagogues like Ipamorelin or CJC No DAC/Ipamorelin could amplify tissue repair. For anti-aging studies, pairing with Epitalon (telomere support) creates comprehensive longevity research. In athletic models, adding IGF-1 LR3 may enhance muscle repair synergy. For joint-specific research, combining with Deca 300 (Nandrolone) could study connective tissue support in anabolic environments.
Proper storage is critical to maintain the stability of this advanced peptide blend.
The Glow peptide blend combines three research compounds: BPC-157 (promotes healing and reduces inflammation), TB-500 (enhances cell migration and tissue repair), and GHK-Cu (stimulates collagen/elastin synthesis and provides antioxidant protection). Together, they're studied for comprehensive effects on skin rejuvenation, scar reduction, connective tissue repair, wound healing, and overall tissue health and resilience in aging or injury models.
Research Use Only: In preclinical studies, administration depends on research goals. For systemic effects, subcutaneous injection in abdominal or thigh areas is common. For localized skin or tissue research, subcutaneous injection near the area of interest (e.g., facial area for skin studies, near joints for connective tissue research) may be used. Topical application (mixed into creams) is also studied for dermatological research. The 60 mg concentration provides flexibility for various administration routes in controlled studies.
Research protocols vary by objective: For skin studies, daily topical application ± subcutaneous administration for 6-8 weeks is common. For injury/tissue repair, daily subcutaneous injection for 4-8 weeks. For systemic anti-aging research, 8-12 week protocols with every-other-day administration. The blend's components have different half-lives: BPC-157/GHK-Cu require frequent dosing; TB-500 provides longer-lasting effects. Many studies use combination approaches (topical + subcutaneous) for comprehensive effects.
Yes, in research settings, the Glow blend is often studied alongside other compounds for enhanced effects. It pairs well with growth hormone secretagogues (like Ipamorelin or CJC-1295) for amplified tissue repair, with Epitalon for comprehensive anti-aging studies, or with individual components at different ratios for specific research objectives. The 60 mg concentration allows for flexible combination research designs while maintaining the core synergistic triad.
Dragon Pharma's Glow 60 mg offers significant research advantages:
Growth Hormone Fragment 176-191 Peptide
Comprehensive Healing & Recovery Peptide Blend
Official distributor of Dragon Pharma products. Pharmaceutical grade research compounds shipped worldwide.
USA Domestic: 4-5 business days
International: 13-15 business days
Important Disclaimer: All products sold on this website are for research purposes only. They are not intended for human consumption or diagnostic use. These products are not drugs and are not approved by the FDA for the treatment, cure, or prevention of any disease or condition. By purchasing from our store, you acknowledge that you are a qualified researcher and understand the proper handling procedures for these compounds. Keep all products out of reach of children and unauthorized persons.
© 2009 - 2026 Dragon Pharma™. All rights reserved.